MediciNova to get US patent for MN-166 to treat brain cancer

Sep. 15, 2022 5:58 AM ETMediciNova, Inc. (MNOV)By: Ravikash, SA News Editor

Business woman signs a patent. Intellectual property protection concept. Patent attorney.

Irina Vodneva/iStock via Getty Images

  • MediciNova (NASDAQ:MNOV) said it will receive a new patent from the U.S. Patent and Trademark Office which covers MN-166 (ibudilast) to treat glioblastoma.
  • The new patent is expected to expire no earlier than February 2039, the company said in a Sept. 14 press release.
  • Glioblastoma is a type of cancer that can occur in the brain or spinal cord.
  • The allowed claims cover a method of treating a patient with glioblastoma or recurrent glioblastoma, wherein a patient expresses unmethylated MGMT, using MN-166 (ibudilast) in combination with one or more other therapeutic agents.
  • "Results of our glioblastoma animal model study showed that median survival was longer in the group that received combination treatment with MN-166 plus temozolomide compared to the group that received the standard treatment of temozolomide alone," said MediciNova Chief Medical Officer Kazuko Matsuda.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.